文献速递肝病消化道肿瘤与早癌消化内镜

肝细胞癌切除与移植的进展

Advances in resection and transplantation for hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2020-01-01

本文综述肝细胞癌外科治疗中当前存在争议的话题,涵盖肝切除与移植、丙型肝炎治愈的影响、非酒精性脂肪性肝炎相关肝细胞癌的上升、非手术局部治疗、分子基因组评估及免疫辅助治疗,强调多学科整合团队诊疗。

要点

  • 丙型肝炎可治愈是近年该领域最具影响的进展,尤其在西方丙型肝炎长期为肝细胞癌主要病因的国家。
  • 非酒精性脂肪性肝炎相关肝细胞癌发病率上升,对外科管理的影响是当前热点。
  • 肝细胞癌诊疗日益需要多学科整合团队协作以获得最佳结局。

核心结论

  • 肝切除与移植均为成熟手段,技术进步与候选者选择改善多为渐进性。
  • 丙型肝炎可治愈是近年最具影响的进展,但其全部意义尚待明确。
  • 肝细胞癌诊疗日益依赖多学科整合团队协作。

研究设计与样本

  • 本文为综述,选取当前存在争议的话题进行讨论并力求呈现平衡观点。

主要发现

  • 丙型肝炎可治愈是近年该领域最具影响的进展,尤其在西方丙型肝炎长期为肝细胞癌主要病因并预测术后不良结局的国家。
  • 非酒精性脂肪性肝炎相关肝细胞癌发病率上升,其对外科管理的影响是当前热点。
  • 随着技术进步,非手术局部治疗作为潜在治愈性手段应用日益增多。
  • 肝细胞癌分子与基因组评估的进展有望实现个体化治疗与预后判断。
  • 免疫治疗作为切除术后辅助治疗的可能作用正在被积极研究。

临床怎么用

  • 肝细胞癌患者的外科治疗应在多学科整合团队框架内进行以获得最佳结局。

局限性

  • 本文为综述,无法在有限篇幅内总结肝细胞癌外科管理的所有重要进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It would be impossible to summarise all of the significant developments in the surgical management of hepatocellular carcinoma (HCC), even just over the past year, in a manuscript of this scope. Thus, we have selected topics for discussion that are the subject of current controversy and have attempted to present balanced points of view. Hepatic resection and transplantation are both mature modalities, and for the most part technical advances and improvements in candidate selection are incremental. The ability to readily cure hepatitis C stands out as the most impactful development in the field over recent years, especially in Western countries where hepatitis C has long been the chief aetiology underlying HCC and a predictor of poor outcomes after surgery, but its full implications remain to be clarified. The rising incidence of non-alcoholic steatohepatitis-related HCC and what it means with regard to surgical HCC management is an area of great current interest. With advancing technology, non-surgical locoregional treatments are gaining increasing application as potentially curative therapies. In addition, the advances in molecular and genomic assessment of HCC hold promise for personalising treatment and prognostication. The possible role of immunotherapy as an adjuvant to resection is being aggressively investigated. While liver surgery maintains an important role, the care of patients with HCC is more and more a team effort and needs to take place in the context of a well-integrated interdisciplinary programme to achieve the best outcomes for patients.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Vibert E, Schwartz M, Olthoff KM, et al. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020. PMID: 31954491. doi:10.1016/j.jhep.2019.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。